Last reviewed · How we verify

Acthar low dose (40 U)

NYU Langone Health · FDA-approved active Small molecule

Acthar low dose (40 U) is a ACTH analog Small molecule drug developed by NYU Langone Health. It is currently FDA-approved for Infantile spasms (West syndrome), Nephrotic syndrome, Rheumatoid arthritis. Also known as: Repository Corticotropin Injection.

Acthar is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.

Acthar is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids. Used for Infantile spasms (West syndrome), Nephrotic syndrome, Rheumatoid arthritis.

At a glance

Generic nameActhar low dose (40 U)
Also known asRepository Corticotropin Injection
SponsorNYU Langone Health
Drug classACTH analog
TargetMelanocortin-2 receptor (MC2R)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Acthar binds to melanocortin-2 receptors on adrenocortical cells, triggering the release of endogenous glucocorticoids and mineralocorticoids. This endogenous steroid production provides anti-inflammatory and immunosuppressive effects. The low-dose formulation (40 U) is used for chronic conditions requiring sustained but modest corticosteroid activity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Acthar low dose (40 U)

What is Acthar low dose (40 U)?

Acthar low dose (40 U) is a ACTH analog drug developed by NYU Langone Health, indicated for Infantile spasms (West syndrome), Nephrotic syndrome, Rheumatoid arthritis.

How does Acthar low dose (40 U) work?

Acthar is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.

What is Acthar low dose (40 U) used for?

Acthar low dose (40 U) is indicated for Infantile spasms (West syndrome), Nephrotic syndrome, Rheumatoid arthritis, Systemic lupus erythematosus, Multiple sclerosis relapse.

Who makes Acthar low dose (40 U)?

Acthar low dose (40 U) is developed and marketed by NYU Langone Health (see full NYU Langone Health pipeline at /company/nyu-langone-health).

Is Acthar low dose (40 U) also known as anything else?

Acthar low dose (40 U) is also known as Repository Corticotropin Injection.

What drug class is Acthar low dose (40 U) in?

Acthar low dose (40 U) belongs to the ACTH analog class. See all ACTH analog drugs at /class/acth-analog.

What development phase is Acthar low dose (40 U) in?

Acthar low dose (40 U) is FDA-approved (marketed).

What are the side effects of Acthar low dose (40 U)?

Common side effects of Acthar low dose (40 U) include Hypertension, Hypokalemia, Hyperglycemia, Insomnia, Mood changes, Increased infection risk.

What does Acthar low dose (40 U) target?

Acthar low dose (40 U) targets Melanocortin-2 receptor (MC2R) and is a ACTH analog.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing